AWARDDELIVERY ORDEROther than small business
Delivery order 75N91021F00002UNIVERSITY OF OKLAHOMA
Overview
Award facts
- Net obligations
- $1.02M
- $1,020,800of $1.02M potential value
- Outlays (paid to date)
- $984.87K
- $984.87K paid of $1.02M obligated$984,872
- Period of performance
- Sep 15, 2021 to Sep 14, 2026
- Ended
- Modifications
- 5
- Latest action Jun 17, 2026
- Contract type
- Delivery order
- PIID 75N91021F00002
Contract value is the most the government could spend; obligations are what it has legally committed; outlays are what it has actually paid.
Description of requirement
PROJECT TITLE: FURTHER EVALUATION OF AMHR2-ED ANTIGENS FOR EPITHELIAL OVARIAN CARCINOMA
Dates and value
- Award date
- Signed on Sep 13, 2021
- Current value
- $1,020,800Base and exercised options
- Potential value (if all options are exercised)
- $1,020,800
- Parent contract vehicle
- 75N91019D00020 (IDC, multiple award) — 15 orders recorded under it
Obligations by fiscal year of action
- FY2026: -$9,191 (de-obligation)
- FY2024: $184,150
- FY2021: $845,841
Total across 3 fiscal years: $1,020,800
Net de-obligation in that fiscal year (obligations withdrawn).
Source: Federal Procurement Data System contract actions as published by SAM.gov and USAspending.gov; latest action recorded Jun 17, 2026. View on USAspending · Recipient on SAM.gov
Recipient
LocationOKLAHOMA CITY, OK
UEIGY8NMUZQXVS7
CAGE code4B862
Business sizeOther than small businessSize at award, per the contracting officer
Organization typeUS government entity
Parent companyUNIVERSITY OF OKLAHOMA
Business types and certifications
Educational institutionU.S. government entity
As represented in SAM.gov at the time of the action.
Subcontracting network
The prime, the subcontractors on this award, and their own subcontractors.
Agency and place
Awarding and funding
- Awarded by
- Funded by
- Department of Health and Human Services
- National Institutes Of Health
- NIH NCI
- Funded from
- National cancer institute (0849)Program activities075-0849Federal accounts (agency financial reports)
Place of performance
- Place of performance
- Oklahoma City, Oklahoma County, Oklahoma 73126-0921
- Congressional district (place of performance)
- OK-05As reported at the time of the action
Classification and competition
Classification
- Product or service (PSC)
- AN12HEALTH R&D SERVICES; HEALTH CARE SERVICES; APPLIED RESEARCH (research and development)
Competition
- Extent competed
- Full and open competitionA
- Solicitation procedures
- Subject to multiple award fair opportunityMAFO
- Set-aside
- No set-aside used
- Contract pricing
- Firm fixed priceJ
- Offers received
- 1
Solicitation and notices
- Solicitation ID
- TORFP 2021 E-07(as reported)
- Solicitation date
- Jul 16, 2021
Contract details
- Subcontracting plan
- Individual subcontract planF
- Major program
- Further evaluation of AMHR2-ED antigens for epithelial ovarian carcinoma
- Certified cost or pricing data
- No
- Commercial procedures
- Commercial products/services procedures not usedD
- Government-furnished property
- Transaction does not use GFE/GFPN
- Bundled requirement
- Not bundledH
- Consolidated requirement
- Not consolidatedD
- Undefinitized action (terms not final)
- No
- Multi-year contract
- No
- Performance-based service acquisition
- No - service where PBA is not used.N
Linked notices
Notice | Notice ID | Type | Link | Posted |
|---|---|---|---|---|
Transaction history
Modification history
- Base award
- Sep 13, 2021Base obligation at award: $845,841
- Latest action
- Jun 17, 2026 — Supplemental agreement (within scope)Modification P00005; obligation change -$9,191
- Latest substantive action
- Jun 17, 2026 — Supplemental agreement (within scope)Modification P00005; obligation change -$9,191
- Actions by type
- Base award1
- Supplemental agreement (within scope)3
- Change order1
- Other administrative action1
Similar awards
PIID | Match | Awardee |
|---|---|---|
All contract data
All contract data
Every other field reported for this award, as of its latest reported action
Competition
- Evaluation preference
- No preference used
- Local area set-aside
- No
- Synopsized publicly (SAM.gov / FedBizOpps)
- Yes
- Simplified procedures for commercial items
- No
- A-76 (FAIR Act) action
- No
Pricing and financing
- Paid by purchase card
- No
- Latest action: change in base and exercised options
- -$9,191
- Latest action: change in base and all options
- -$9,191
Socio-economic and policy
- Inherently governmental functions
- Other functionsOT
- Recovered materials and sustainability
- No clauses included and no sustainability includedC
- EPA-designated product
- Not requiredE
- Clinger-Cohen Act planning (IT)
- No
- Walsh-Healey Act (materials and supplies)
- Yes
Place and origin
- Domestic or foreign entity
- Other U.S. entity (e.g. government)B
- Country of product or service origin
- United statesUSA
- Place of manufacture
- Not a manufactured end productC
Structure
- Award or IDV
- Award
- Award type
- Delivery orderC
- Parent vehicle type
- IDCB
- Parent vehicle: multiple or single award
- Multiple awardM
- Parent vehicle agency
- National Institutes Of Health7529
- Awarding agency code
- 7500
- Awarding sub-tier code
- 7529
- Contracting office code
- 75N910
- Transactions recorded under this award key
- 6
Funding
- Funding agency code
- 7500
- Funding sub-tier code
- 7529
- Funding office code
- 75N910
- Treasury accounts
- 075-2021/2021-0849-000
- Object classes
- 25.5: Research and development contracts
- Disaster or emergency funding (DEFC)
- Q: Not Designated Nonemergency/Emergency/Disaster/Wildfire Suppression